Regarding the fourth dose of Covid vaccine, “there is not yet enough evidence to recommend a second booster” vaccine. This was reiterated by Marco Cavaleri, head of Vaccines and Covid-19 therapeutic products of the European drug agency Ema, explaining that “before reaching a conclusion on whether or not it is appropriate in general,” we must evaluate the effectiveness of current vaccines in the time and understand how the Omicron wave will continue “. Read also” An exception – he added – are the additional doses for severely immunocompromised people. I want to reiterate that for these patients, who should already have received three doses of an mRna vaccine as part of the primary vaccination course, a fourth dose would be the first booster “, the equivalent of the third dose for the general population,” and this the additional dose is therefore already recommended. “” We are evaluating the data on the efficacy of vaccines and anti-Covid treatments against the highly transmissible sub-variant Omicron BA.2 “, the so-called Omicron 2.” For now, vaccines appear to protect against this sub-variant as they do against Omicron “, he pointed out during the periodic update for the press. The EMA is then evaluating the third heterologous dose 3 months after the second, instead of after 4.” We are considering updating the interval between cycles primary and booster dose when two different Covid-19 vaccines are given. This interval can be reduced to 3 months “, announced Cavaleri. While the responses to both the anti-Covid pill molnupiravir by Merck (MSD outside the US and Canada) could arrive” next week “from the European drug agency EMA. already in use in Italy, and on the possible approval of Moderna’s Spikevax * anti-Covid vaccine for children aged 6-11. “Next week – he explained – at the meeting of the CHMP Committee for Medicinal Products for Human Use, “The dossier on” molnupiravir and also a potential expansion of Spikevax approval in 6-11 year olds will be discussed. “